Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  thiotepa
Find trials that include:  Any drugs shown
Results 1-22 of 22 for your search:
Start Over
Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma
Status: Temporarily closed
Phase: Phase III
Type: Treatment
Age: 10 and under
Trial IDs: ARET0321, NCI-2009-00421, CDR0000573987, COG-ARET0321, NCT00554788
Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 10 to 69
Trial IDs: MT2005-21, NCI-2010-01700, 2006LS032, UMN-2006LS032, UMN-MT2005-21, UMN-0608M90586, NCT00432094
Mismatched Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 65 and under
Trial IDs: IUCRO-0184, NCI-2011-02351, NCT00593554
Reduced Intensity Donor Stem Cell Transplant in Treating Patients with Hematologic Malignancies
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 11D.247, NCI-2011-02345, 1795, 2011-31, NCT01384513
Combination Chemotherapy with or without Autologous Stem Cell Transplant in Treating Patients with Central Nervous System B-cell Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 to 75
Trial IDs: CALGB 51101, NCI-2012-00110, CDR0000721927, NCT01511562
Donor Progenitor Cell and Natural Kill Cell Transplant in Treating Younger Patients with High-Risk Hematologic Malignancies
Status: Active
Phase: Phase II
Type: Treatment
Age: 21 and under
Trial IDs: HAPNK1, NCI-2013-00609, NCT01807611
Selective Depletion of CD45RA+ T Cells from Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care
Age: 21 and under
Trial IDs: 2660.00, NCI-2013-00958, 2660, NCT01858740
Selective Depletion of CD45RA+ T Cells from Allogeneic Peripheral Blood Stem Cell Grafts from HLA-Matched Related and Unrelated Donors in Preventing GVHD
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 14 to 60
Trial IDs: 2684.00, NCI-2014-01301, NCT02220985
Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Recurrent or Progressive Germ Cell Tumors
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: CCI-09-00196, NCI-2013-01195, NCT01270742
High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients with High-Risk Neuroblastoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 29 and under
Trial IDs: 2015LS108, NCI-2015-02023, CPRC #2015LS108, MT2015-25, NCT02605421
Laboratory-Treated Donor Cord Blood Cell Transplant in Treating Patients with Relapsed or Refractory Hematologic Malignancies
Status: Active
Phase: Phase I
Type: Treatment
Age: 1 to 80
Trial IDs: 2010-0658, NCI-2011-03742, NCT01471067
Genetically Modified Donor Stem Cell Transplant Followed by Zoledronic Acid in Treating Younger Patients with Relapsed/Refractory Hematologic Malignancies or High Risk Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 7 months to 21 years
Trial IDs: UW13090, NCI-2015-01163, NCT02508038
Cyclophosphamide in Treating Patients with Hematological Malignancies after Undergoing Donor Stem Cell Transplant
Status: Active
Phase: No phase specified
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 11D.51, NCI-2011-02342, 2010-54, NCT01349101
Donor Peripheral Blood Stem Cell Transplant in Treating Patients with Hematological Malignancies
Status: Active
Phase: No phase specified
Type: Treatment
Age: 0 to 19
Trial IDs: 12-053, NCI-2012-00822, NCT01598025
Reduced-Intensity Conditioning before Donor Stem Cell Transplant in Treating Patients with High-Risk Hematologic Malignancies
Status: Active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: 12D.501, NCI-2012-02762, 2012-67, NCT01760655
Partially-Matched Donor Stem Cell Transplant in Treating Younger Patients with High-Risk Hematologic Malignancies
Status: Active
Phase: No phase specified
Type: Treatment
Age: Not specified
Trial IDs: SCT 0813, NCI-2015-00141, CMH 13H11, CMH SCT 0813, SCT 0813 Haplo, NCT02053545
CD34+ Stem Cell Selection in Preventing Graft-Versus-Host Disease in Younger Patients with Malignant Disease Undergoing Donor Stem Cell Transplant
Status: Active
Phase: No phase specified
Type: Treatment
Age: Under 22
Trial IDs: AAAK8060, NCI-2014-00137, NCT02061800
Start Over